Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
US FDA Approves Novel Antipsychotic Agent Rexulti: Otsuka, Lundbeck
Otsuka Pharmaceutical and H. Lundbeck A/S have announced that the US FDA has approved the novel antipsychotic agent Rexulti (brexpiprazole). The drug is indicated for adjunctive therapy for adults with major depressive disorder (MDD) and for the treatment of adults…
To read the full story
Related Article
- Otsuka Files Schizophrenia Med Brexpiprazole in Japan
January 10, 2017
- Rexulti OK’ed for Schizophrenia Maintenance Therapy in US
September 27, 2016
BUSINESS
- Drug Makers, Wholesalers See No Major Disruptions after Aomori Quake
December 10, 2025
- SanBio Clears Hurdle for Akuugo Shipments, Heads to Reimbursement Talks
December 10, 2025
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
- LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
- Kazuo Nakamura, Founder of Japan’s First CRO, Dies at 78
December 9, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…